Table 2.
Results of subgroup analysis.
| ORR | PFS | OS1 | OS2 | |||||
| Pooled OR [95% CI] | I 2 | Pooled HR [95% CI] | I 2 | Pooled HR [95% CI] | I 2 | Pooled HR [95% CI] | I 2 | |
| Cutoff values | ||||||||
| 1% | 0.66 [0.15, 2.90] | 84.8% | 1.97 [1.36, 2.85] | 22.8% | 5.82 [1.09, 30.96] | 56.9% | 3.34 [1.31, 8.56] | 50.3% |
| 5% | 0.56 [0.29, 1.07] | 0% | 0.56 [0.29, 1.07] | 38.8% | 0.56 [0.29, 1.06] | 0% | 0.88 [0.36, 2.15] | 61.3% |
| IHC assays | ||||||||
| ab58810 | / | / | 0.40 [0.25, 0.64] | 0% | 0.39 [0.17, 0.87] | 38.5% | / | / |
| E1L3N | / | / | / | / | / | / | 1.22 [0.21, 7.22] | 83.0% |
| 22C3 | / | / | 1.88 [1.38, 2.57] | 16.0% | 2.88 [1.58, 5.26] | 21.6% | 1.86 [1.12, 3.07] | 55.0% |
| SP142 | / | / | 2.37 [0.78, 7.17] | 94.4% | / | / | 1.29 [0.62, 2.68] | 83.5% |
| Line of TKI treatment | ||||||||
| 1st | 0.51 [0.17, 1.56] | 73.7% | 2.07 [1.16, 3.68] | 88.8% | 1.24 [0.70,2.20] | 45.4% | / | / |
| 1st/≥2nd | 0.57 [0.34, 0.96] | 0.0% | 1.08 [0.61, 1.91] | 81.4% | 1.34 [0.48, 3.79] | 85.9% | / | / |
CI = confidence interval, EGFR = epidermal growth factor receptor, HR = hazard ratio, ORR = objective response rate, OS = overall survival, OS1 = represents OS of EGFR-TKI treatment, OS2 = represents OS in EGFR-mutant cohort, PD-L1 = programmed death-ligand 1, PFS = progression-free survival, TKI = tyrosine kinase inhibitor.